Saturday, July 21, 2018 12:30:12 PM
Ultraz2,
I think that without a clear home run Linda will lose control of any chance to develop any products in the future. She as much as admitted that NWBO would seriously run the risk of not being an ongoing concern by the end of this year. She may keep control of key technology if there is no home run but everyone would be against her at that point. There would be enough bad blood between those who had supported her through thick and thin to keep her from getting support to prove it out before something else advanced or big pharma bought most of the control of the company from disgruntled longs at fire sale prices. She has no chance to restore her reputation without a homerun because she is the one that coined that phrase with regard to DCVax-L. Best wishes.
I think that without a clear home run Linda will lose control of any chance to develop any products in the future. She as much as admitted that NWBO would seriously run the risk of not being an ongoing concern by the end of this year. She may keep control of key technology if there is no home run but everyone would be against her at that point. There would be enough bad blood between those who had supported her through thick and thin to keep her from getting support to prove it out before something else advanced or big pharma bought most of the control of the company from disgruntled longs at fire sale prices. She has no chance to restore her reputation without a homerun because she is the one that coined that phrase with regard to DCVax-L. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
